Basic Information
| Drug ID | DDPD00904 |
|
| Drug Name | Ondansetron | |
| Molecular Weight | 293.363 | |
| Molecular Formula | C18H19N3O | |
| CAS Number | 99614-02-5 | |
| SMILES | CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2 | |
| External Links | ||
| DRUGBANK | DB00904 | |
| T3DB | T3D2925 | |
| PubChem Compound | 4595 | |
| PDR | 2288 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 2.4 | - | 2.4 | - | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 58.0 | % | 56-60 | % | Tablet, PO, oral; | DRUGBANK | Bioavailability | 62.0 | % | 62±15 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 39.0 | ng/ml | 39(31-48) | ng/ml | PO, oral; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | C Max | 102.0 | ng/ml | 102(64-136) | ng/ml | The Pharmacological Basis of Therapeutics |
| T Max | 1.0 | h | 1.0(0.8-1.5) | h | PO, oral; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | |
| Metabolic | 10.0 | % | <10 | % | Urinary excretion; Unchanged drug; human, homo sapiens; | DRUGBANK | |
| Clearance | 0.38 | L/h/kg | 0.38 | L/h/kg | normal,healthy; adults; | DRUGBANK | Clearance | 0.29 | L/h/kg | 0.26-0.32 | L/h/kg | normal,healthy; Elderly; | DRUGBANK | Clearance | 0.35 | L/h/kg | 5.9±2.6 | ml/min/kg | Female, women ↓ ;Children ↑ ;Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.35 | L/h/kg | 5.8 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 160.0 | L | ~160 | L | DRUGBANK | Volume of Distribution | 1.9 | L/kg | 1.9±0.05 | L/kg | Elderly → ;Hepatic cirrhosis, cirr → ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.8 | L/kg | 1.8 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 3.5 | h | 3-4 | h | PO, oral; | DRUGBANK | Half-life | 3.5 | h | 3-4 | h | intravenous injection, IV; | DRUGBANK | Half-life | 7.0 | h | 6-8 | h | Elderly; | DRUGBANK | Half-life | 3.5 | h | 3.5±1.2 | h | Children ↓ ;Hepatic cirrhosis, cirr ↑ ;Age ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 3.4 | h | 3.4 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Eliminate Route | 5.0 | % | 5 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 73.0 | % | ~73 | % | plasma proteins; | DRUGBANK | Protein Binding | 73.0 | % | 73±2 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for infants | 0.1 | mg/kg | 0.1 | mg/kg | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for infants | 0.15 | mg/kg/dose | 0.15 | mg/kg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for infants | 16.0 | mg/dose | 16 | mg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for children | 0.15 | mg/kg/dose | 0.15 | mg/kg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for children | 16.0 | mg/dose | 16 | mg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for children | 0.15 | mg/kg/dose | 0.15 | mg/kg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for children | 16.0 | mg/dose | 16 | mg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for children | 12.0 | mg/day | 12 | mg/day | PO, oral | Zuplenz | ondansetron | PDR |
| Max dose for children | 0.15 | mg/kg/dose | 0.15 | mg/kg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for children | 16.0 | mg/dose | 16 | mg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for children | 16.0 | mg/day | 16 | mg/day | PO, oral | Zuplenz | ondansetron | PDR |
| Max dose for adolescents | 0.15 | mg/kg/dose | 0.15 | mg/kg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for adolescents | 16.0 | mg/dose | 16 | mg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for adolescents | 16.0 | mg/day | 16 | mg/day | PO, oral | Zuplenz | ondansetron | PDR |
| Max dose for adults | 24.0 | mg/day | 24 | mg/day | PO, oral | Zuplenz | ondansetron | PDR |
| Max dose for adults | 0.45 | mg/kg/day | 0.45 | mg/kg/day | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for adults | 48.0 | mg/day | 16 | mg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for geriatric | 24.0 | mg/day | 24 | mg/day | PO, oral | Zuplenz | ondansetron | PDR |
| Max dose for geriatric | 0.45 | mg/kg/day | 0.45 | mg/kg/day | intravenous injection, IV | Zuplenz | ondansetron | PDR |
| Max dose for geriatric | 16.0 | mg/dose | 16 | mg/dose | intravenous injection, IV | Zuplenz | ondansetron | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1